Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | AGER | Q15109 | 1/20 | 0.54 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676896 | 0.93 | MRGPRX4 (0.55) | MRGPRX4MCL1AGERPTPN7PPARD | |
| SCHEMBL10253493 | 0.88 | MCL1 (0.60) | MRGPRX4MCL1AGERPTPN7PPARD | |
| SCHEMBL3930793 | 0.84 | MCL1 (0.60) | MCL1PTPN7PPARDPTGDR2ALOX15 | |
| SCHEMBL22346861 | 0.83 | AGER (0.56) | MCL1AGERPTPN7PPARDPPARA | |
| SCHEMBL29689327 | 0.83 | AGER (0.56) | MCL1AGERPTPN7PPARDPPARA | |
| SCHEMBL14501966 | 0.81 | PSEN1 (0.49) | MRGPRX4MCL1AGERTDP1LMNA | |
| SCHEMBL22602085 | 0.81 | MCL1 (0.60) | MCL1AGERPTPN7PPARDPPARA | |
| SCHEMBL17896566 | 0.80 | SMN1; SMN2 (0.55) | MCL1AGERPTPN7PPARDPPARA | |
| SCHEMBL118785 | 0.80 | MCL1 (0.72) | MRGPRX4MCL1PTPN7PPARDALOX15 | |
| SCHEMBL29540672 | 0.80 | MCL1 (0.72) | MRGPRX4MCL1PTPN7PPARDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188071-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2025-06-12 | — | — | US | disclosed |
| US-12258338-B2 | Modulators of the integrated stress response pathway | EVOTEC INTERNATIONAL GMBH (DE) | 2025-03-25 | — | — | US | disclosed |
| CN-113993850-B | Modulators of integrated stress response pathways | 埃沃特克国际有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20220227747-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC (UK) LIMITED (GB) | 2022-07-21 | — | — | US | disclosed |
| CN-113993850-A | Modulators of integrated stress response pathways | 埃沃特克国际有限责任公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020216766-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216766-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2020-10-29 | — | — | WO | disclosed |
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258338-B2 | Modulators of the integrated stress response pathway | CRHR2, CRHR1, CRH | MRGPRX4 77/4885MCL1 4325/4885AGER 3323/4885 |
| US-20250188071-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | MRGPRX4 77/4885MCL1 4325/4885AGER 3323/4885 |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | CNR1, AVPR1A, OPRL1 | MRGPRX4 231/4885MCL1 2085/4885AGER 1578/4885 |
| US-20220227747-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | MRGPRX4 77/4885MCL1 4325/4885AGER 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.